Home  |  Contact

Cellosaurus BON-1 (CVCL_3985)

Cell line name BON-1
Synonyms Bon-1; BON1; BON
Accession CVCL_3985
Secondary accession CVCL_B390
Resource Identification Initiative To cite this cell line use: BON-1 (RRID:CVCL_3985)
Comments Doubling time: 1.5 +- 0.4 days (PubMed=29330294); 46 +- 0.72 hours (PubMed=32884006).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: SNP array analysis.
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
Sequence variations
Disease Pancreatic serotonin-producing neuroendocrine tumor (NCIt: C4446)
Serotonin-producing neuroendocrine tumor of pancreas (ORDO: Orphanet_506090)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_WV97 (BON1 RR1)CVCL_WV98 (BON1 RR2)CVCL_A1AU (BON1-MEN1-KO)
Sex of cell Male
Age at sampling 28Y
Category Cancer cell line
STR profile Source(s): PubMed=29444910

Markers:
AmelogeninX,Y
CSF1PO10,11
D5S8189,12
D7S8209
D13S31711,12
D16S53910,11
D21S1128,33.2
TH018
TPOX9
vWA18,19

Run an STR similarity search on this cell line
Web pages http://www.cells-talk.com/index.php/page/copelibrary?key=BON
Publications

PubMed=1712329; DOI=10.5555/uri:pii:0016508591900045
Evers B.M., Townsend C.M. Jr., Upp J.R. Jr., Allen E., Hurlbut S.C., Kim S.W., Rajaraman S., Singh P., Reubi J.-C., Thompson J.C.
Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth.
Gastroenterology 101:303-311(1991)

PubMed=7978888; DOI=10.1111/j.1749-6632.1994.tb17289.x
Evers B.M., Ishizuka J., Townsend C.M. Jr., Thompson J.C.
The human carcinoid cell line, BON. A model system for the study of carcinoid tumors.
Ann. N. Y. Acad. Sci. 733:393-406(1994)

PubMed=8108375; DOI=10.1097/00006676-199401000-00013
Parekh D., Ishizuka J., Townsend C.M. Jr., Haber B., Beauchamp R.D., Karp G., Kim S.W., Rajaraman S., Greeley G. Jr., Thompson J.C.
Characterization of a human pancreatic carcinoid in vitro: morphology, amine and peptide storage, and secretion.
Pancreas 9:83-90(1994)

PubMed=19295186; DOI=10.1159/000209330
Siddique Z.-L., Drozdov I., Floch J., Gustafsson B.I., Stunes K., Pfragner R., Kidd M., Modlin I.M.
KRJ-I and BON cell lines: defining an appropriate enterochromaffin cell neuroendocrine tumor model.
Neuroendocrinology 89:458-470(2009)

PubMed=22538498; DOI=10.1159/000338793
Grozinsky-Glasberg S., Shimon I., Rubinfeld H.
The role of cell lines in the study of neuroendocrine tumors.
Neuroendocrinology 96:173-187(2012)

PubMed=22929519; DOI=10.3791/4218
Wong C., Vosburgh E., Levine A.J., Cong L., Xu E.Y.
Human neuroendocrine tumor cell lines as a three-dimensional model for the study of human neuroendocrine tumor therapy.
J. Vis. Exp. 66:e4218.1-e4218.7(2012)

PubMed=25612765; DOI=10.1530/JME-14-0304
Vandamme T., Peeters M., Dogan F., Pauwels P., Van Assche E., Beyens M., Mortier G., Vandeweyer G., de Herder W., Van Camp G., Hofland L.J., Op de Beeck K.
Whole-exome characterization of pancreatic neuroendocrine tumor cell lines BON-1 and QGP-1.
J. Mol. Endocrinol. 54:137-147(2015)

PubMed=26087898; DOI=10.1016/j.cancergen.2015.04.002
Boora G.K., Kanwar R., Kulkarni A.A., Pleticha J., Ames M., Schroth G., Beutler A.S., Banck M.S.
Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines.
Cancer Genet. 208:374-381(2015)

PubMed=29330294; DOI=10.1158/1541-7786.MCR-17-0163
Benten D., Behrang Y., Unrau L., Weissmann V., Wolters-Eisfeld G., Burdak-Rothkamm S., Stahl F.R., Anlauf M., Grabowski P., Mobs M., Dieckhoff J., Sipos B., Fahl M., Eggers C., Perez D., Bockhorn M., Izbicki J.R., Lohse A.W., Schrader J.
Establishment of the first well-differentiated human pancreatic neuroendocrine tumor model.
Mol. Cancer Res. 16:496-507(2018)

PubMed=29444910; DOI=10.1530/ERC-17-0445
Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R., Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Endocr. Relat. Cancer 25:367-380(2018)

PubMed=29895527; DOI=10.1530/ERC-18-0159
Aristizabal Prada E.T., Spottl G., Maurer J., Lauseker M., Koziolek E.J., Schrader J., Grossman A., Pacak K., Beuschlein F., Auernhammer C.J., Nolting S.
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Endocr. Relat. Cancer 25:893-908(2018)

CLPUB00598
Behrang Y.
Establishment and characterization of a new human, highly differentiated and functionally active tumor model of a pancreatic neuroendocrine tumor.
Thesis MD (2020), University of Hamburg, Germany

PubMed=32884006; DOI=10.1038/s41598-020-71516-7
Monazzam A., Li S.-C., Wargelius H., Razmara M., Bajic D., Mi J., Bergquist J., Crona J., Skogseid B.
Generation and characterization of CRISPR/Cas9-mediated MEN1 knockout BON1 cells: a human pancreatic neuroendocrine cell line.
Sci. Rep. 10:14572-14572(2020)

Cross-references
Cell line databases/resources cancercelllines; CVCL_3985
Anatomy/cell type resources BTO; BTO:0003856
Encyclopedic resources Wikidata; Q54797946
Polymorphism and mutation databases Cosmic; 721017
Cosmic; 1620107
Cosmic; 1879411
Cosmic; 2433550
Cosmic; 2530675
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number17